NEW YORK (Reuters) - Drugmaker Mylan Inc (>> Mylan NV), which is trying to launch a generic form of GlaxoSmithKline's (>> GlaxoSmithKline plc) Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the standards it must meet.

The FDA sent Mylan a letter earlier this year in which it declined to approve the product, but the company had not previously disclosed the issues at hand. Mylan declined to set a timeline for launch for the product.

(Reporting by Caroline Humer; Editing by Chizu Nomiyama)

Stocks treated in this article : GlaxoSmithKline plc, Hikma Pharmaceuticals Plc, Mylan NV